ST Pharm Co.,Ltd. (KOSDAQ:237690)

Paramount Global Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	274,450	273,751	284,992	249,322	165,642	124,109
Other Revenue	-	-0	-	-0	-0	-
Revenue	274,450	273,751	284,992	249,322	165,642	124,109
Revenue Growth (YoY)	-4.06%	-3.94%	14.31%	50.52%	33.47%	33.08%
Cost of Revenue	180,723	180,147	175,248	162,140	110,333	105,760
Gross Profit	93,727	93,605	109,744	87,182	55,309	18,349
Selling, General & Admin	40,253	40,069	41,120	37,665	28,034	19,496
Research & Development	22,664	22,108	30,450	26,306	18,218	13,204
Other Operating Expenses	435.16	464.7	1,069	863.35	761.82	1,820
Operating Expenses	66,888	65,912	76,232	69,330	49,731	37,166
Operating Income	26,838	27,693	33,512	17,851	5,578	-18,817
Interest Expense	-7,738	-7,738	-6,106	-2,868	-5,157	-644.58
Interest & Investment Income	4,571	4,571	2,440	1,236	939.37	618.04
Earnings From Equity Investments	-246.09	-246.09	-	-	-	-
Currency Exchange Gain (Loss)	13,298	13,298	1,809	3,607	3,361	-1,922
Other Non Operating Income (Expenses)	-10,916	-5,823	-236.68	683.87	65.55	693.3
EBT Excluding Unusual Items	25,807	31,755	31,418	20,511	4,786	-20,072
Gain (Loss) on Sale of Investments	12,390	12,390	-8,063	-628.83	147.24	3,258
Gain (Loss) on Sale of Assets	-1,446	-1,446	-0.62	-644.73	-3,673	-10.89
Asset Writedown	47.79	47.79	-	-	-	-
Pretax Income	36,799	42,747	23,354	19,237	1,260	-16,825
Income Tax Expense	9,050	10,283	5,831	1,721	-2,117	-3,670
Earnings From Continuing Operations	27,749	32,464	17,523	17,516	3,377	-13,155
Minority Interest in Earnings	1,772	2,248	2,058	484.29	-65.27	1,008
Net Income	29,521	34,712	19,581	18,000	3,312	-12,147
Net Income to Common	29,521	34,712	19,581	18,000	3,312	-12,147
Net Income Growth	34.02%	77.27%	8.78%	443.46%	-	-
Shares Outstanding (Basic)	20	20	19	19	19	19
Shares Outstanding (Diluted)	20	20	19	19	19	19
Shares Change (YoY)	5.53%	3.70%	-	0.77%	0.05%	-
EPS (Basic)	1488.44	1779.72	1041.07	957.00	177.50	-651.11
EPS (Diluted)	1488.44	1779.72	1041.00	957.00	177.00	-651.11
EPS Growth	27.01%	70.96%	8.78%	440.68%	-	-
Free Cash Flow	-1,343	26,646	-41,946	-53,448	-44,522	-37,924
Free Cash Flow Per Share	-67.73	1366.16	-2230.12	-2841.64	-2385.36	-2032.81
Dividend Per Share	500.000	500.000	-	-	-	-
Gross Margin	34.15%	34.19%	38.51%	34.97%	33.39%	14.78%
Operating Margin	9.78%	10.12%	11.76%	7.16%	3.37%	-15.16%
Profit Margin	10.76%	12.68%	6.87%	7.22%	2.00%	-9.79%
Free Cash Flow Margin	-0.49%	9.73%	-14.72%	-21.44%	-26.88%	-30.56%
EBITDA	52,992	53,275	56,538	35,452	19,992	-4,749
EBITDA Margin	19.31%	19.46%	19.84%	14.22%	12.07%	-3.83%
D&A For EBITDA	26,154	25,582	23,027	17,600	14,414	14,068
EBIT	26,838	27,693	33,512	17,851	5,578	-18,817
EBIT Margin	9.78%	10.12%	11.76%	7.16%	3.37%	-15.16%
Effective Tax Rate	24.59%	24.05%	24.97%	8.95%	-	-
Advertising Expenses	-	1,221	705.83	324.5	83.11	141.16

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.